The ADAMTSL1 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs-like 1) protein belongs to the ADAMTS-like family, a subgroup of the ADAMTS superfamily that lacks the catalytic protease domain. Primarily secreted into the extracellular matrix (ECM), ADAMTSL1 is implicated in ECM organization, cell adhesion, and tissue development. It interacts with fibrillin-1. a key component of microfibrils, and modulates TGF-β signaling pathways, influencing processes like fibrosis, inflammation, and connective tissue homeostasis. Genetic studies link ADAMTSL1 mutations to disorders such as geleophysic dysplasia and Weill-Marchesani-like syndrome, characterized by short stature, skeletal abnormalities, and cardiac defects.
ADAMTSL1 antibodies are essential tools for studying its expression, localization, and molecular interactions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of its role in developmental biology and disease. Commercially available antibodies target specific epitopes, often within its thrombospondin or leucine-rich repeat domains. Recent research focuses on ADAMTSL1's dual role in both promoting and inhibiting TGF-β activity, highlighting its context-dependent functions in tissue remodeling and cancer progression. Validating antibody specificity remains critical due to structural similarities within the ADAMTS/ADAMTSL families. Understanding ADAMTSL1 mechanisms may offer therapeutic insights for connective tissue disorders and fibrotic diseases.